Departments of Obstetrics and Gynecology,1 Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas2
Received 7 February 2005/ Returned for modification 31 March 2005/ Accepted 25 July 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The human placenta has an extraordinary capacity to synthesize estrogens by aromatization of C19/androgen precursors secreted by the fetal adrenals (39). The aromatization reaction is catalyzed by an enzyme complex comprised of two polypeptides, NADPH-cytochrome P450 reductase and a unique form of cytochrome P450, aromatase P450 (P450arom, product of the CYP19 gene) (45). In most vertebrates, CYP19 expression is restricted to the gonads and to discrete nuclei of the brain; however, in humans, it also is expressed in the syncytiotrophoblast layer of the placenta, stromal cells of adipose tissue, bone, fetal liver, and in vascular smooth muscle and endothelial cells (23, 40). Expression of the human CYP19 (hCYP19) gene in various estrogen-producing tissues is driven by tissue-specific promoters upstream of tissue-specific alternative first exons, which encode the 5' untranslated regions of hCYP19 mRNA transcripts. These alternative first exons, located from
110 bp to
100,000 bp upstream of the hCYP19 translation initiation site in exon II, are alternatively spliced onto a common site just upstream of the translation start site so that the protein synthesized by each of these tissues is identical (31). In placenta, the majority of the hCYP19 mRNA transcripts contain 5' untranslated sequences encoded by exon I.1, which lies
95,000 bp upstream of the start site of translation in exon II (23). Studies using transgenic mice suggest that as little as 246 bp of hCYP19 exon I.1 5' flanking DNA and 103 bp of exon I.1 are sufficient to direct reporter gene expression exclusively to the placenta, specifically to the labyrinthine and trophoblast giant cell layers (22, 24). Since mouse placenta does not express aromatase, these findings indicate that placental transcription factors that mediate hCYP19 gene expression are conserved between mouse and human, while the genetic response elements that bind these factors are not.
Estrogen synthesis by human placenta is increased markedly after the ninth week of gestation (9) in association with cytotrophoblast invasion, remodeling, and enlargement of the uterine arterioles. This invasion results in a pronounced increase in blood flow to the intervillous space and concomitant increase in O2 availability to cells of the floating chorionic villi (18). When cytotrophoblasts isolated from midgestation human placenta are cultured in a 20% O2 environment, they spontaneously fuse to form the syncytiotrophoblast; this occurs in concert with a marked induction of hCYP19 gene expression and of aromatase activity (19). By contrast, when cytotrophoblasts are cultured in a 2% O2 (hypoxic) environment (similar to the placental O2 tension during the first trimester of gestation), they manifest increased rates of DNA synthesis and fail to fuse to form the syncytiotrophoblast, and hCYP19 expression remains undetectable (19). Thus, by use of this culture system, we are able to mimic morphological and biochemical events associated with placental differentiation.
In previous studies to define the mechanisms for O2 regulation of trophoblast differentiation, we identified a basic-helix-loop-helix (bHLH) transcription factor, Mash-2 (mammalian achaete/scute homologue-2), that manifested elevated levels of expression in freshly isolated human cytotrophoblasts, declined with syncytiotrophoblast differentiation in a 20% O2 environment, and was maintained at elevated levels by hypoxia (19). Overexpression of Mash-2 in cultured human trophoblast cells maintained in 20% O2 caused marked inhibition of hCYP19 expression and blocked syncytiotrophoblast differentiation (19).
In more recent studies, we observed that Mash-2 is primarily a cytoplasmic protein that does not bind to the hCYP19 gene directly; rather, it acts to increase expression of the bHLH-zipper transcription factors, upstream stimulatory factor 1 (USF1) and USF2, which bind as heterodimers to E-box sequences within the 5' flanking region and in placenta-specific exon I.1 of the hCYP19 gene to inhibit hCYP19I.1 promoter activity (20). In contrast to Mash-2, USF proteins are localized to the nucleus. Nuclear levels of USF1 and USF2 were elevated in freshly isolated cytotrophoblasts and in trophoblasts cultured in 2% O2 and declined with syncytiotrophoblast differentiation in 20% O2. Importantly, overexpression of USF1 in human trophoblasts cultured in 20% O2 blocked syncytiotrophoblast differentiation and induction of hCYP19 gene expression (20). Surprisingly, unlike USF proteins, which were markedly induced by hypoxia and by Mash-2 overexpression, USF1 (19) and USF2 (B. Jiang and C. R. Mendelson, unpublished observations) mRNA levels were unaffected. These findings suggest that hypoxia-induced expression of USF1/2 proteins is due to changes in mRNA translatability and/or protein stability. Thus, increased protein levels of USF1/2 mediate the inhibitory effects of hypoxia and of Mash-2 on syncytiotrophoblast differentiation and hCYP19 gene expression.
Our goal in the present study was to define the mechanisms whereby O2 tension alters USF protein expression and differentiation of human trophoblast cells. We observed that proteasome inhibitors blocked the O2-mediated decline in USF1/2 protein levels, increased their binding to E boxes surrounding hCYP19 promoter I.1, and prevented syncytiotrophoblast differentiation and induction of hCYP19 gene expression. These findings together with the observation that increased O2 tension promoted USF polyubiquitylation, suggest that increased degradation of USFs via the proteasome pathway plays a key role in O2-mediated trophoblast differentiation and induction of hCYP19 gene expression during human placental development. The finding that hypoxia and Mash-2 overexpression with associated increases in USFs markedly induced cyclin B1 expression and increased the proportion of cultured trophoblast cells at the G2/M boundary further suggests that increased USF1/2 expression may promote cytotrophoblast proliferation at the expense of differentiation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
siRNA transfection. One day before transfection, JEG3 cells were trypsinized, counted, and plated in 60-mm dishes in growth medium without antibiotics to achieve 30 to 50% confluence at the time of transfection. Small interfering RNA (siRNA)-Oligofectamine complexes were prepared as follows: 10 µl of 20 µM USF1 or USF2 siRNA or USF1 plus USF2 siRNA oligonucleotide (Ambion, Inc., Austin, TX) was added to 175 µl of Opti-MEM I "reduced serum medium" (Invitrogen, Carlsbad, CA) and incubated for 5 to 10 min. Three microliters of Oligofectamine (Invitrogen, Carlsbad, CA) was combined with 12 µl of Opti-MEM for addition to each well of a six-well plate. The diluted oligonucleotides were combined with the diluted Oligofectamine (total volume, 200 µl), mixed gently, and incubated for 15 to 20 min at room temperature to allow the siRNA-Oligofectamine complexes to form. The growth medium was removed, and the cells were washed once with medium without serum. Medium without serum (800 µl) was added to each well containing cells, followed by addition of siRNA-Oligofectamine complexes (200 µl). The cells were then maintained at 37°C in a CO2 incubator for 4 h. Growth medium containing three times the normal concentration of serum (500 µl) was then added to each dish without removing the transfection mixture. After culture for 48 h, the transfected cells were scraped from the dishes, passed through a 21-gauge needle for cell disruption, and centrifuged at 10,000 x g. Total cell lysates (20 µg of protein) were analyzed for USF1 and USF2 protein by immunoblotting or placed in RNA lysis solution (Ambion, Inc., Austin, TX) for RNA isolation and analysis of hCYP19 mRNA or 28S rRNA by Northern blotting.
Infection of trophoblast cells with recombinant adenoviruses. Freshly isolated cytotrophoblasts plated at a density of 2 x 106 cells per 35-mm dish in DMEM containing 10% FBS were infected with recombinant adenoviruses containing a fusion gene comprised of 501 bp of hCYP19 exon I.1 5' flanking sequence linked to hGH (human growth hormone gene) as reporter at a multiplicity of infection (MOI) of 0.5 and cultured in a 20% O2 environment in the absence (dimethyl sulfoxide [DMSO] vehicle) or presence of the proteasome inhibitors, LLnL (N-acetyl-L-leucyl-L-leucyl-L-norleucinal) (Sigma, St. Louis, MO) and MG-115 (Calbiochem, La Jolla, CA). After an overnight incubation, the medium was removed and replaced with fresh DMEM containing 2% FBS, with or without the proteasome inhibitors. The cells were incubated for up to 72 h; medium was collected and replaced daily and analyzed for hGH by radioimmunoassay (Nichols Institute Diagnostics, San Juan Capistrano, CA).
In other experiments, recombinant adenoviruses containing CMV-Mash-2 (where CMV is the cytomegalovirus promoter) or CMV-ß-galactosidase (CMV-ß-gal, as a control), constructed as described previously (19), were used to infect freshly isolated cytotrophoblasts at an MOI of 5.0 and cultured in a 2% or 20% O2 environment. The infected cells were analyzed for stage of the cell cycle or for expression of cyclin B1 by immunofluorescence, as described below.
Cell cycle analysis. Human trophoblasts cultured for 72 h in a 2% or 20% O2 environment or in a 20% O2 environment after infection with recombinant adenoviruses expressing Mash-2 or ß-Gal, were trypsinized and fixed in 70% ethanol overnight at 4°C. After fixation, the cells were washed in phosphate-buffered saline (PBS) and incubated with RNase (50 µg/ml; Roche, Indianapolis, IN) for 1 h and stained with propidium iodide (25 µg/ml; Sigma-Aldrich, St. Louis, MO) for 15 min at 4°C. The stained cells were analyzed by FACScan using CellQUEST software (Becton Dickinson, Franklin, NJ).
Immunofluorescence staining. Freshly isolated cytotrophoblasts were plated on glass coverslips and infected with recombinant adenoviruses containing CMV-Mash-2 (MOI, 5) or the same amount of CMV-ß-gal overnight (as described above) and then cultured for 3 days in DMEM containing 2% FBS in an atmosphere of 20% O2. Cells were fixed in methanol (100%) at 20°C for 6 min and then incubated with antibody to cyclin B1 (5 µg/ml) (Pharmingen, San Diego, CA) in PBS containing 0.5% bovine serum albumin (Sigma, St. Louis, Mo.) for 45 min. Goat anti-rabbit immunoglobulin G (IgG)-fluorescein conjugate (Molecular Probes, Eugene, OR) was used as secondary antibody. Slides were examined by immunofluorescence microscopy using a B-2 filter for fluorescein isothiocyanate (Nikon, Kanagawa, Japan).
Morphological analysis. Cytotrophoblasts were cultured on glass coverslips in DMEM containing 2% FBS in a 20% O2 environment in the absence or presence of proteasome inhibitors, MG-115 or MG-132 (Calbiochem, La Jolla, CA). After cells were cultured for 16 h in 20% O2, medium was removed, half of the dishes were rinsed with PBS, and the cells were fixed in 75% ethanol. Fresh medium without proteasome inhibitors was added to the remaining dishes, which were cultured for an additional 16 h and then rinsed and fixed in 75% ethanol. Hematoxylin and eosin Y were used to stain nuclei and cytoplasm, respectively. Morphology was analyzed by light microscopy.
Coimmunoprecipitation and immunoblot analysis. Nuclear and cytosolic fractionation and immunoblotting procedures have been described in detail previously (20). For coimmunoprecipitation, nuclear and cytosolic fractions were isolated from trophoblast cells that had been cultured in 2% O2 or 20% O2 for 16 h in the absence (DMSO) or presence of the proteasome inhibitors LLnL, MG-115, or MG-132. For immunoprecipitation and immunoblot analysis, cytosolic (500 µg) and nuclear proteins (150 µg) were precleared by incubation with nonimmune rabbit IgG (0.25 µg/ml) for 30 min at 4°C and then incubated with 1 µg of USF1 or USF2 rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 1 h at 4°C, followed by addition of 20 µl of protein A agarose beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The mixture was then incubated on a rotating mixer at 4°C overnight. The protein A-agarose beads were washed with RIPA buffer (1x PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) four times, and bound proteins were eluted using 40 µl of 1x SDS sample buffer. The eluates (40 µl) were electrophoresed on 12% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose membranes (Midwest Scientific, Valley Park, MO), which were incubated with mouse monoclonal antiubiquitin antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Sheep anti-mouse IgG horseradish peroxidase-linked F(ab')2 fragment (Amersham Pharmacia Biotech Inc., Piscataway, NJ) was used as a secondary antibody. For standard immunoblot analysis of USF1/2, nuclear and cytosolic proteins (20 µg) were electrophoresed on 12% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose membranes. Membranes were blocked using 5% milk and incubated with antibodies to either human USF1 or human USF2 (0.5 µg/ml). Donkey anti-rabbit IgG horseradish peroxidase-linked F(ab')2 fragment (Amersham Pharmacia Biotech Inc., Piscataway, NJ) was used as a secondary antibody. Proteins assessed by coimmunoprecipitation and immunoblotting were detected using an ECL kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ) following the manufacturer's protocol.
Northern blot analysis. Total RNA was extracted using an RNA purification kit according to the manufacturer's protocol (Ambion Inc., Austin, TX) from JEG3 cells that were transfected with either USF1 siRNA, USF2 siRNA, or USF1 siRNA plus USF2 siRNA and incubated for 48 h. Aliquots (20 µg) of total RNA were size fractionated on a 7.4% formaldehyde-0.9% agarose gel, transferred to Zeta-Probe blotting membrane (Bio-Rad Laboratories, Inc. Hercules, CA), and hybridized for 2 h at 65°C to radiolabeled cDNA probes for hCYP19 mRNA (19). The cDNAs were 32P-labeled using a Prime-It RmT random primer labeling kit (Stratagene, La Jolla, Calif.). After samples were washed, relative levels of mRNA were assessed by autoradiography. The Northern blots were stripped and reprobed using a radiolabeled 28S cDNA (American Type Culture Collection, Manassas, VA) to assess loading and transfer of RNA.
Tritiated water assay of aromatase activity in placental cells. Freshly isolated cytotrophoblast cells were cultured in a 20% O2 environment in the absence or presence of proteasome inhibitors (LLnL and MG-115) for 16 h. Aromatase activity was assayed using a tritiated water assay as described previously (1). 1ß-[3H]androstenedione (NEN Life Science Products, Boston, MA) was added to the culture medium during the last 1 h of incubation. The medium was then removed and placed in ice-cold 30% (wt/vol) trichloroacetic acid. The incorporation of tritium from 1ß-[3H]androstenedione into water was assayed in aqueous scintillation fluid after extraction with 4 volumes of chloroform and 1 volume of dextran-charcoal suspension. The adherent cells were analyzed for protein (29). Aromatase activity is expressed as picomoles of 1ß-[3H]androstenedione metabolized to estrogen/min/mg protein.
EMSA. Nuclear proteins isolated from trophoblasts cultured in a 20% O2 environment in the absence or presence of proteasome inhibitors (LLnL or MG-132) for 16 h were incubated with double-stranded oligonucleotides (GIBCO, Carlsbad, CA; Integrated DNA Technologies, Inc., Coralville, IA) containing three E-box sequences (underlined) within placenta-specific exon I.1 and its 5' flanking region (20) (E1 at 325 bp, 5'-ACTCCCATGACACTTGCTGAGGTCTT-3'; E2 at 58 bp, 5'-TTTGTTCAATCACATGCTTCAGTCAT-3'; E3 at +26 bp, 5'-GAGGGCTGAACACGTGGAGGCAAACA-3') (GenBank accession no. M30795). Binding activity was analyzed by electrophoretic mobility shift assay (EMSA) as described in detail previously (20). Briefly, the nuclear proteins were incubated for 1 h at 4°C in binding buffer in the absence or presence of IgG (1 µg) for human USF1 (hUSF1) or hUSF2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Radiolabeled E1, E2, or E3 oligonucleotides were added to the reaction mixture, and the incubation was continued for another 30 min at room temperature, before separation on 5% native polyacrylamide gels and visualization by autoradiography.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
Peptide aldehyde proteasome inhibitors, such as MG-115 and MG132, also inhibit lysosomal and calcium activated proteases (32). To verify specificity for the proteasome, we also tested the effects of the epoxyketone containing natural product epoxomicin, which has been found to specifically target the 26S proteasome (33). We observed that epoxomicin at a concentration as low as 200 nM caused a pronounced increase in USF1 and USF2 protein levels and markedly inhibited hCYP19 mRNA levels in human trophoblast cells cultured in 20% O2 (data not shown). These findings indicate that O2-mediated degradation of USF1/2 likely occurs via the 26S proteasome pathway.
Proteasome inhibitors increase USF1 and USF2 binding to E-boxes in DNA within hCYP19 exon I.1 and its 5' flanking region. We previously identified three potential E-box binding sites for USF1/2 upstream and within placenta-specific hCYP19 exon I.1 (E1, 325 bp; E2, 58 bp; E3, +26 bp) (20). By EMSA, we found that binding activity for all three E-boxes was increased in nuclear extracts of freshly isolated cytotrophoblasts compared to syncytiotrophoblast, but that only the E2 and E3 boxes had the capacity to bind USF1/2 (20). In the present study, EMSA was used to analyze the effects of proteasome inhibitors on USF binding activity in trophoblast nuclear extracts for the E2 and E3 boxes; nuclear protein binding to the E1 box was analyzed as a control. As can be seen in Fig. 5, binding activity for the E2 and E3 boxes of nuclear proteins isolated from human trophoblasts cultured in 20% O2 for 16 h in the presence of the two proteasome inhibitors was increased markedly compared to extracts from cells incubated with the DMSO vehicle. The finding that the specific binding complexes were completely supershifted by either USF1 or USF2 antibody indicates that the proteasome inhibitors increased binding of USF1 and USF2 proteins as a heterodimer to E2 and E3 boxes (Fig. 5). By contrast, no effect of the proteasome inhibitors was observed for nuclear protein binding to the E1 box. These findings suggest that like hypoxia, proteasome inhibitors inhibit hCYP19 gene expression by increasing USF1/2 binding to the E2 and E3 boxes.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
The goal of this study was to further define the mechanisms whereby USFs sense changes in O2 tension and mediate hypoxia inhibition of trophoblast differentiation and CYP19 gene expression. siRNA technology was applied to JEG3 cells to assess the inhibitory role of endogenous USFs on hCYP19 gene expression. JEG3 is a choriocarcinoma cell line that is cytotrophoblast-like. In this regard, these cells are highly proliferative and manifest low levels of hCYP19 gene expression (21). Interestingly, JEG3 cells have increased expression levels of USF1/2, compared to primary cultures of human trophoblast cells (B. Jiang and C. R. Mendelson, unpublished observations). We observed that cotransfection of JEG3 cells with siRNAs corresponding to both USF1 and USF2 caused a pronounced decrease in nuclear levels of USF1 and USF2 proteins and a marked induction of hCYP19 mRNA levels. These findings indicate that increased expression of endogenous USFs in the choriocarcinoma cells suppresses hCYP19 gene expression, which is a manifestation of differentiative function.
Based on our previous finding that changes in O2 tension altered USF protein levels but had no effect on USF1/2 mRNA, we hypothesized that O2 regulation of trophoblast differentiation and hCYP19 gene expression may be mediated by alterations in USF1 and USF2 protein degradation via the proteasome pathway. To test this hypothesis, we analyzed the effects of proteasome inhibitors on human trophoblast cells in primary culture. We found that these agents increased USF1/2 protein levels and binding to the E-boxes surrounding hCYP19 promoter I.1. This was associated with inhibitory effects of the proteasome inhibitors on aromatase activity, hCYP19 gene expression, hCYP19 promoter activity, and trophoblast cell fusion and differentiation. Furthermore, we observed increased levels of polyubiquitylated USF1 and USF2 in cytoplasm of human trophoblast cells cultured in 20% O2 in the presence of proteasome inhibitors, compared to cells cultured in a 2% O2-containing environment. We propose that with increased blood flow through the placental spiral arteries after the ninth week of human gestation with an associated increase in local O2 tension, USF1/2 levels decline because of increased proteasomal degradation. This, in turn, results in enhanced syncytiotrophoblast differentiation with increased biosynthesis of steroid and polypeptide hormones.
A number of bHLH transcription factors containing PAS (Per-aryl hydrocarbon receptor nuclear translocator [ARNT]-Sim) domains have been found to be hypoxia inducible and mediate enhanced expression of target genes, including those encoding glycolytic enzymes, glucose transporters, and growth factors that induce erythropoiesis and angiogenesis (4, 7, 38). These bHLH-PAS domain transcription factors include hypoxia inducible factor 1
(HIF-1
) (38), human endothelial PAS domain protein 1 (EPAS-1/HIF-2
) (8), and their common obligate heterodimeric partner ARNT/HIF-1ß (46). Protein levels of HIF-1
(38) and EPAS-1 (47) decline under normoxic conditions because of increased proteasomal degradation triggered by posttranslational hydroxylation of a conserved proline residue in its oxygen-dependent degradation domain. This, in turn, promotes recruitment of von Hippel-Lindau tumor-suppressor protein (VHL), the recognition component of an E3 ubiquitin ligase, leading to polyubiquitylation and targeting of HIF-1
and EPAS-1 to the 26S proteasome. Increased expression of HIF-1
(5), VHL, and EPAS-1 (13) was observed in human trophoblast villous explants cultured under hypoxic conditions; levels of these proteins declined when explants were cultured in 20% O2. Although we have observed that EPAS-1 levels decline in human trophoblast cells during culture in 20% O2 and are induced by hypoxia and Mash-2 overexpression (20), we were unable to detect EPAS-1 binding to the E2 and E3 boxes surrounding hCYP19 promoter I.1 (20). This is likely due to the fact that HIF transcription factors bind as heterodimers with ARNT to DNA sequences termed "hypoxia response elements" that have a GTG common to USF binding sites as the 3' half-site (which binds ARNT) and a unique 5' half-site (43). Only ARNT homodimers have the capacity to bind to the palindromic E-box core sequences (CACGTG) (42, 43) that bind USF1/2 heterodimers. Furthermore, HIF-1
protein levels are low in our primary human trophoblast cultures and appear to be unaffected by changes in O2 tension or proteasome inhibitors (B. Jiang and C. R. Mendelson, unpublished observations). Using coimmunoprecipitation, we were unable to detect a direct interaction between USF1/2 and VHL, although in the same coimmunoprecipitation analysis, HIF-1
in HeLa cells incubated with CoCl2 interacted strongly with VHL (B. Jiang and C. R. Mendelson, unpublished observations). Thus, it is likely that USF1 and USF2 interact with another E3 ligase(s) to mediate their proteasomal degradation.
On the other hand, a role for VHL in placental differentiation is likely, since mouse embryos that are homozygous null for the vhl gene die at embryonic day 9.5 (E9.5) to E10.5 because of a defect in placental vasculogenesis (15). Furthermore, Arnt/ embryos also die by E10.5 because of a failure of labyrinthine trophoblast development and placental vascularization (27). The Arnt/ placentas also manifest marked decreases in diploid spongiotrophoblasts and increased numbers of giant cells (2). Interestingly, ARNT was found to be required for differentiation of trophoblast stem cells into spongiotrophoblasts under hypoxia conditions (2). On the other hand, Hif-1
/ embryos die by E11 because of neural tube defects, lack of cephalic vascularization, and increased cell death and cardiovascular malformations (17, 37), while Epas-1/ mice die after E12.5 because of presumed defects in catecholamine homeostasis. Neither Hif-1
- nor Epas-1-deficient embryos manifest defects in placental development or vascularization. Thus, it is likely that ARNT acts either as a homodimer (42) or as a heterodimer with another bHLH transcription factor to promote labyrinthine trophoblast development. The finding that embryonic lethality occurs in mice that are homozygous for targeted deletion in the usf2 gene and either homozygous or heterozygous for a mutation in the usf1 gene suggests that USF proteins are essential for embryonic development (41). However, their role in placental development remains unknown since the cause of embryonic death in these mutant mice was not reported.
The mechanism(s) whereby increased expression levels of USF1/2 prevent syncytiotrophoblast differentiation has not been defined. In previous studies, we found that hypoxia and overexpression of Mash-2 markedly increased DNA synthesis in cultured trophoblast cells (19). In the present study, we found that this was associated with a pronounced increase in the number of cells at the G2/M transition and induction in cytoplasmic levels of cyclin B1, a protein that plays a critical role in control of the G2/M transition and progression through the somatic cell cycle (see reference 35 for a review). As mentioned above, Mash-2 overexpression markedly enhances USF1/2 nuclear protein levels in human trophoblast cells (20). Interestingly, it has been found that USF activates expression of the gene for cyclin B1 in HeLa cells (6). Furthermore, it was observed that USF DNA-binding activity was enhanced in a G2-dependent manner (6). Thus, it appears that increased levels of USF1/2 in cytotrophoblasts cultured in a hypoxic environment may promote cell proliferation and block cellular pathways leading to differentiation.
The mechanisms whereby USFs inhibit hCYP19 gene expression have not been determined. USFs are known to serve both as transcriptional activators (11, 34) and as repressors of a number of target genes, including the ABCA1 transporter (48), Xenopus MyoD (30), and the rabbit CYP19A1 gene (44). USF1 was found to inhibit transcription of the rabbit CYP19A1 gene by competing with ARNT for binding to the promoter (44). In the case of Xenopus MyoD, USF was found to block autoactivation of the promoter by competing for binding with myogenic activating transcription factors (30). We postulate that under hypoxic conditions in human trophoblast cells, increased nuclear levels of USF1/2 may compete with transcriptional activators for binding to the E2 and E3 boxes. USF1/2 binding, in turn, may facilitate the recruitment of transcriptional corepressors leading to a closing of chromatin structure and silencing of hCYP19 expression. We further suggest that with the developmental increase in placental vascularization and increased O2 availability to trophoblast cells, the inhibitory USFs are degraded, which may allow placenta-specific transcription factors to bind to the E boxes and promote placenta-specific expression. A potential candidate is the bHLH-leucine zipper transcription factor, TFEB-A, which is highly and selectively expressed in placenta (28). Interestingly, like hCYP19, TFEB has numerous tissue-specific first exons suggesting its control via alternative promoters (28). In recent studies, we found that a fusion gene comprised of 246 bp of hCYP19 exon I.1 5' flanking DNA and 103 bp of exon I.1, containing the E2 and E3 boxes, was expressed in a placenta-specific and developmentally regulated manner in transgenic mice (24). Studies are in progress to define the transcription factors bound to the E2 and E3 boxes under hypoxic and normoxic conditions and their roles in developmental and placental cell-specific regulation of hCYP19 promoter I.1 activity.
| ACKNOWLEDGMENTS |
|---|
This work was funded by Public Health Service grant 5-R01 DK031206 from the National Institute of Diabetes and Digestive and Kidney Diseases (C.R.M.).
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Adelman, D. M., M. Gertsenstein, A. Nagy, M. C. Simon, and E. Maltepe. 2000. Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes Dev. 14:3191-3203.
3. Alsat, E., P. Wyplosz, A. Malassine, J. Guibourdenche, D. Porquet, C. Nessmann, and D. Evain-Brion. 1996. Hypoxia impairs cell fusion and differentiation process in human cytotrophoblast, in vitro. J. Cell. Physiol. 168:346-353.[CrossRef][Medline]
4. Bruick, R. K., and S. L. McKnight. 2002. Transcription. Oxygen sensing gets a second wind. Science 295:807-808.
5. Caniggia, I., H. Mostachfi, J. Winter, M. Gassmann, S. J. Lye, M. Kuliszewski, and M. Post. 2000. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFß(3). J. Clin. Investig. 105:577-587.[Medline]
6. Cogswell, J. P., M. M. Godlevski, M. Bonham, J. Bisi, and L. Babiss. 1995. Upstream stimulatory factor regulates expression of the cell cycle-dependent cyclin B1 gene promoter. Mol. Cell. Biol. 15:2782-2790.[Abstract]
7. Ema, M., K. Hirota, J. Mimura, H. Abe, J. Yodoi, K. Sogawa, L. Poellinger, and Y. Fujii-Kuriyama. 1999. Molecular mechanisms of transcription activation by HLF and HIF1
in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 18:1905-1914.[CrossRef][Medline]
8. Ema, M., S. Taya, N. Yokotani, K. Sogawa, Y. Matsuda, and Y. Fujii-Kuriyama. 1997. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1
regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA 94:4273-4278.
9. Everett, R. B., and P. C. MacDonald. 1979. Endocrinology of the placenta. Annu. Rev. Med. 30:473-488.[CrossRef][Medline]
10. Fox, H. 1970. Effect of hypoxia on trophoblast in organ culture. A morphologic and autoradiographic study. Am. J. Obstet. Gynecol. 107:1058-1064.[Medline]
11. Gao, E., Y. Wang, J. L. Alcorn, and C. R. Mendelson. 2003. Transcription factor USF2 is developmentally regulated in fetal lung and acts together with USF1 to induce SP-A gene expression. Am. J. Physiol. 284:L1027-L1036.
12. Genbacev, O., R. Joslin, C. H. Damsky, B. M. Polliotti, and S. J. Fisher. 1996. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J. Clin. Investig. 97:540-550.[Medline]
13. Genbacev, O., A. Krtolica, W. Kaelin, and S. J. Fisher. 2001. Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro. Dev. Biol. 233:526-536.[CrossRef][Medline]
14. Genbacev, O., Y. Zhou, J. W. Ludlow, and S. J. Fisher. 1997. Regulation of human placental development by oxygen tension. Science 277:1669-1672.
15. Gnarra, J. R., J. M. Ward, F. D. Porter, J. R. Wagner, D. E. Devor, A. Grinberg, M. R. Emmert-Buck, H. Westphal, R. D. Klausner, and W. M. Linehan. 1997. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA 94:9102-9107.
16. Huot, R. I., J. M. Foidart, and K. Stromberg. 1979. Effects of culture conditions on the synthesis of human chorionic gonadotropin by placental organ cultures. In Vitro 15:497-502.[Medline]
17. Iyer, N. V., L. E. Kotch, F. Agani, S. W. Leung, E. Laughner, R. H. Wenger, M. Gassmann, J. D. Gearhart, A. M. Lawler, A. Y. Yu, and G. L. Semenza. 1998. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1
. Genes Dev. 12:149-162.
18. Jauniaux, E., A. L. Watson, J. Hempstock, Y. P. Bao, J. N. Skepper, and G. J. Burton. 2000. Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in human early pregnancy failure. Am. J. Pathol. 157:2111-2122.
19. Jiang, B., A. Kamat, and C. R. Mendelson. 2000. Hypoxia prevents induction of aromatase expression in human trophoblast cells in culture: potential inhibitory role of the hypoxia-inducible transcription factor Mash-2 (mammalian achaete-scute homologous protein-2). Mol. Endocrinol. 14:1661-1673.
20. Jiang, B., and C. R. Mendelson. 2003. USF1 and USF2 mediate inhibition of human trophoblast differentiation and CYP19 gene expression by Mash-2 and hypoxia. Mol. Cell. Biol. 23:6117-6128.
21. Kamat, A., J. L. Alcorn, C. Kunczt, and C. R. Mendelson. 1998. Characterization of the regulatory regions of the human aromatase (P450arom) gene involved in placenta-specific expression. Mol. Endocrinol. 12:1764-1777.
22. Kamat, A., K. H. Graves, M. E. Smith, J. A. Richardson, and C. R. Mendelson. 1999. A 500-bp region, approximately 40 kb upstream of the human CYP19 (aromatase) gene, mediates placenta-specific expression in transgenic mice. Proc. Natl. Acad. Sci. USA 96:4575-4580.
23. Kamat, A., M. M. Hinshelwood, B. A. Murry, and C. R. Mendelson. 2002. Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol. Metab. 13:122-128.[CrossRef][Medline]
24. Kamat, A., M. E. Smith, J. M. Shelton, J. A. Richardson, and C. R. Mendelson. 2005. Genomic regions that mediate placental cell-specific and developmental regulation of human CYP19 (aromatase) gene expression in transgenic mice. Endocrinology 146:2481-2488.
25. Kaufmann, P. 1982. Development and differentiation of the human placental villous tree. Bibl. Anat. 22:29-39.
26. Kliman, H. J., J. E. Nestler, E. Sermasi, J. M. Sanger, and J. F. Strauss III. 1986. Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology 118:1567-1582.[Abstract]
27. Kozak, K. R., B. Abbott, and O. Hankinson. 1997. ARNT-deficient mice and placental differentiation. Dev. Biol. 191:297-305.[CrossRef][Medline]
28. Kuiper, R. P., M. Schepens, J. Thijssen, E. F. Schoenmakers, and A. G. van Kessel. 2004. Regulation of the MiTF/TFE bHLH-LZ transcription factors through restricted spatial expression and alternative splicing of functional domains. Nucleic Acids Res. 32:2315-2322.
29. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:265-275.
30. Lun, Y., M. Sawadogo, and M. Perry. 1997. Autoactivation of Xenopus MyoD transcription and its inhibition by USF. Cell Growth Differ. 8:275-282.[Abstract]
31. Means, G. D., M. S. Mahendroo, C. J. Corbin, J. M. Mathis, F. E. Powell, C. R. Mendelson, and E. R. Simpson. 1989. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem. 264:19385-19391.
32. Mellgren, R. L. 1997. Specificities of cell permeant peptidyl inhibitors for the proteinase activities of µ-calpain and the 20 S proteasome. J. Biol. Chem. 272:29899-29903.
33. Meng, L., R. Mohan, B. H. Kwok, M. Elofsson, N. Sin, and C. M. Crews. 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 96:10403-10408.
34. Nowak, M., A. Helleboid-Chapman, H. Jakel, G. Martin, D. Duran-Sandoval, B. Staels, E. M. Rubin, L. A. Pennacchio, M. R. Taskinen, J. Fruchart-Najib, and J. C. Fruchart. 2005. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol. Cell. Biol. 25:1537-1548.
35. Porter, L. A., and D. J. Donoghue. 2003. Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog. Cell Cycle Res. 5:335-347.[Medline]
36. Ringler, G. E., and J. F. Strauss III. 1990. In vitro systems for the study of human placental endocrine function. Endocr. Rev. 11:105-123.[Medline]
37. Ryan, H. E., J. Lo, and R. S. Johnson. 1998. HIF-1
is required for solid tumor formation and embryonic vascularization. EMBO J. 17:3005-3015.[CrossRef][Medline]
38. Semenza, G. L. 2001. HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107:1-3.[CrossRef][Medline]
39. Simpson, E. R., and P. C. MacDonald. 1981. Endocrine physiology of the placenta. Annu. Rev. Physiol. 43:163-188.[CrossRef][Medline]
40. Simpson, E. R., Y. Zhao, V. R. Agarwal, M. D. Michael, S. E. Bulun, M. M. Hinshelwood, S. Graham-Lorence, T. Sun, C. R. Fisher, K. Qin, and C. R. Mendelson. 1997. Aromatase expression in health and disease. Rec. Prog. Horm. Res. 52:185-213.
41. Sirito, M., Q. Lin, J. M. Deng, R. R. Behringer, and M. Sawadogo. 1998. Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice. Proc. Natl. Acad. Sci. USA 95:3758-3763.
42. Sogawa, K., R. Nakano, A. Kobayashi, Y. Kikuchi, N. Ohe, N. Matsushita, and Y. Fujii-Kuriyama. 1995. Possible function of Ah receptor nuclear translocator (Arnt) homodimer in transcriptional regulation. Proc. Natl. Acad. Sci. USA 92:1936-1940.
43. Swanson, H. I., W. K. Chan, and C. A. Bradfield. 1995. DNA binding specificities and pairing rules of the Ah Receptor, ARNT, and SIM proteins. J. Biol. Chem. 270:26292-26302.
44. Takahashi, Y., K. Nakayama, S. Itoh, Y. Fujii-Kuriyama, and T. Kamataki. 1997. Inhibition of the transcription of CYP1A1 gene by the upstream stimulatory factor 1 in rabbits. Competitive binding of USF1 with AhR · Arnt complex. J. Biol. Chem. 272:30025-30031.
45. Thompson, E. A., Jr., and P. K. Siiteri. 1974. The involvement of human placental microsomal cytochrome P-450 in aromatization. J. Biol. Chem. 249:5373-5378.
46. Wang, G. L., B. H. Jiang, E. A. Rue, and G. L. Semenza. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92:5510-5514.
47. Wiesener, M. S., H. Turley, W. E. Allen, C. Willam, K. U. Eckardt, K. L. Talks, S. M. Wood, K. C. Gatter, A. L. Harris, C. W. Pugh, P. J. Ratcliffe, and P. H. Maxwell. 1998. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1
. Blood 92:2260-2268.
48. Yang, X. P., L. A. Freeman, C. L. Knapper, M. J. Amar, A. Remaley, H. B. Brewer, Jr., and S. Santamarina-Fojo. 2002. The E-box motif in the proximal ABCA1 promoter mediates transcriptional repression of the ABCA1 gene. J Lipid Res. 43:297-306.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||